Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial to Evaluate Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

NCT06179303 is registered in ClinicalTrials.gov with University of Washington as lead sponsor.

NCT NCT06179303
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06179303 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial to Evaluate Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer
Lead sponsor
University of Washington
Phase
Phase 2
Overall status
Recruiting
Start date
July 22, 2024
Completion date
June 1, 2028
Enrollment
60 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

anatomic stage iii breast cancer ajcc v8, anatomic stage iv breast cancer ajcc v8, locally advanced unresectable her2-negative breast carcinoma, locally advanced unresectable hormone receptor-positive breast carcinoma, metastatic her2-negative breast carcinoma, metastatic hormone receptor-positive breast carcinoma